Kenji Chamoto

6.5k total citations · 4 hit papers
85 papers, 4.4k citations indexed

About

Kenji Chamoto is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Kenji Chamoto has authored 85 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Immunology, 41 papers in Oncology and 15 papers in Molecular Biology. Recurrent topics in Kenji Chamoto's work include Immune Cell Function and Interaction (44 papers), Immunotherapy and Immune Responses (34 papers) and T-cell and B-cell Immunology (23 papers). Kenji Chamoto is often cited by papers focused on Immune Cell Function and Interaction (44 papers), Immunotherapy and Immune Responses (34 papers) and T-cell and B-cell Immunology (23 papers). Kenji Chamoto collaborates with scholars based in Japan, United States and Germany. Kenji Chamoto's co-authors include Tasuku Honjo, Takashi Nishimura, Partha S. Chowdhury, Daiko Wakita, Alok Kumar, Junzo Hamanishi, Yoshiko Iwai, Hidemitsu Kitamura, Takayuki Ohkuri and Tsuguhide Takeshima and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Nature Communications.

In The Last Decade

Kenji Chamoto

84 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer immunotherapies targeting the PD-1 signaling pathway

2017 488 citations Kenji Chamoto, Tasuku Honjo et al. profile →
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity

2017 314 citations Kenji Chamoto, Partha S. Chowdhury et al. profile →
PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8+ T Cells and Facilitates Anti–PD-1 Therapy

2018 268 citations Partha S. Chowdhury, Kenji Chamoto et al. Cancer Immunology Research profile →
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1

2023 95 citations Kenji Chamoto, Tomonori Yaguchi et al. Nature reviews. Immunology profile →

Peers

Countries citing papers authored by Kenji Chamoto

Since Specialization

Citations

This map shows the geographic impact of Kenji Chamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenji Chamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenji Chamoto more than expected).

Fields of papers citing papers by Kenji Chamoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenji Chamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenji Chamoto. The network helps show where Kenji Chamoto may publish in the future.

Co-authorship network of co-authors of Kenji Chamoto

This figure shows the co-authorship network connecting the top 25 collaborators of Kenji Chamoto. A scholar is included among the top collaborators of Kenji Chamoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenji Chamoto. Kenji Chamoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ICOS+CD4+ T cells define a high susceptibility to anti–PD-1 therapy–induced lung pathogenesis 2025 ·JCI Insight ·(unknown), Kosaku Murakami, Tomonori Yaguchi, Kenji Chamoto, Hiroaki Ozasa, Hironori Yoshida, Mirei Shirakashi, Katsuhiro Ito, Yoshihiro Komohara, Yukio Fujiwara, Hiromu Yano, (unknown), (unknown), Tomohiro Terada, Toyohiro Hirai, Hirotake Tsukamoto	1
2	Chemoproteomic Identification of Spermidine-Binding Proteins and Antitumor-Immunity Activators 2024 ·Journal of the American Chemical Society ·(unknown), (unknown), (unknown), (unknown), Shin‐ichi Sato, Tasuku Honjo, Kenji Chamoto, Motonari Uesugi	7
3	Spermidine – an old molecule with a new age-defying immune function 2023 ·Trends in Cell Biology ·Kenji Chamoto, Baihao Zhang, Masaki Tajima, Tasuku Honjo, Sidonia Fagarasan	34
4	The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study 2023 ·Frontiers in Immunology ·Takashi Kurosaki, Kenji Chamoto, Shinichiro Suzuki, (unknown), Seiichiro Mitani, Kaoru Tanaka, Hisato Kawakami, Yo Kishimoto, (unknown), Katsuhiro Ito, Toshiyuki Sato, (unknown), (unknown), Yasutaka Chiba, Tomonori Yaguchi, Koichi Omori, Takashi Kobayashi, Kazuhiko Nakagawa, Tasuku Honjo, Hidetoshi Hayashi	12
5	Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1 breakdown → 2023 ·Nature reviews. Immunology ·Kenji Chamoto, Tomonori Yaguchi, Masaki Tajima, Tasuku Honjo	95
6	Current issues and perspectives in PD-1 blockade cancer immunotherapy 2020 ·International Journal of Clinical Oncology ·Kenji Chamoto, Ryusuke Hatae, Tasuku Honjo	117
7	PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8+ T Cells and Facilitates Anti–PD-1 Therapy breakdown → 2018 ·Cancer Immunology Research ·Partha S. Chowdhury, Kenji Chamoto, Alok Kumar, Tasuku Honjo	268
8	Role of PD-1 in Immunity and Diseases 2017 ·Current topics in microbiology and immunology ·Kenji Chamoto, (unknown), Tasuku Honjo	150
9	Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy 2015 ·Cancer Immunology Research ·Toshiki Ochi, Munehide Nakatsugawa, Kenji Chamoto, Shinya Tanaka, Yūki Yamashita, Tingxi Guo, Hiroshi Fujiwara, Masaki Yasukawa, Marcus O. Butler, Naoto Hirano	29
10	Detection of murine post-pneumonectomy lung regeneration by 18FDG PET imaging 2012 ·EJNMMI Research ·Barry C. Gibney, Mi‐Ae Park, Kenji Chamoto, Alexandra B. Ysasi, Moritz A. Konerding, Akira Tsuda, Steven J. Mentzer	12
11	Alveolar macrophage dynamics in murine lung regeneration 2011 ·Journal of Cellular Physiology ·Kenji Chamoto, Barry C. Gibney, Maximilian Ackermann, Grace S. Lee, Lin Miao, Moritz A. Konerding, Akira Tsuda, Steven J. Mentzer	40
12	Local Radiation Therapy Inhibits Tumor Growth through the Generation of Tumor-Specific CTL: Its Potentiation by Combination with Th1 Cell Therapy 2010 ·Cancer Research ·Tsuguhide Takeshima, Kenji Chamoto, Daiko Wakita, Takayuki Ohkuri, Yuji Togashi, Hiroki Shirato, Hidemitsu Kitamura, Takashi Nishimura	201
13	A Th17-polarized cell population that has infiltrated the lung requires cells that convert to IFN-γ production in order to induce airway hyperresponsiveness 2010 ·International Immunology ·Shigeru Ashino, Daiko Wakita, (unknown), Yoichiro Iwakura, Kenji Chamoto, Takayuki Ohkuri, Hidemitsu Kitamura, Takashi Nishimura	18
14	IFN-γ-dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model 2009 ·Carcinogenesis ·Daiko Wakita, Kenji Chamoto, Takayuki Ohkuri, Yoshinori Narita, Shigeru Ashino, Kentaro Sumida, Hiroyoshi Nishikawa, Hiroshi Shiku, Yuji Togashi, Hidemitsu Kitamura, Takashi Nishimura	31
15	ASB16165, a novel inhibitor for phosphodiesterase 7A (PDE7A), suppresses IL-12-induced IFN-γ production by mouse activated T lymphocytes 2009 ·Immunology Letters ·(unknown), Masao Murakawa, Megumi Goto, Yoshitaka Tanaka, Hidekazu Inoue, (unknown), (unknown), Yasuhiro Hayashi, Kazuhiro Nagahira, (unknown), Takashi Nakatsuka, Kenji Chamoto, Yoshiaki Fukuda, Takashi Nishimura	38
16	IL-6–dependent spontaneous proliferation is required for the induction of colitogenic IL-17–producing CD8+ T cells 2008 ·The Journal of Experimental Medicine ·Masaki Tajima, Daiko Wakita, Daisuke Noguchi, Kenji Chamoto, Yue Zhang, Kazunori Fugo, Harumichi Ishigame, Yoichiro Iwakura, Hidemitsu Kitamura, Takashi Nishimura	146
17	A5-05: Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in powerful therapeutic antitumor immunity to murine lung cancer 2007 ·Journal of Thoracic Oncology ·Hiroshi Yokouchi, Koichi Yamazaki, Kenji Chamoto, Satoshi Oizumi, Hirotoshi Dosaka‐Akita, Takashi Nishimura, Masaharu Nishimura	3
18	Natural killer T cells from interleukin‐4‐deficient mice are defective in early interferon‐γ production in response to α‐galactosylceramide 2007 ·Cancer Science ·Yuji Togashi, Kenji Chamoto, Daiko Wakita, (unknown), Yoichiro Iwakura, (unknown), Hidemitsu Kitamura, Takashi Nishimura	4
19	The critical role of type‐1 innate and acquired immunity in tumor immunotherapy 2004 ·Cancer Science ·Hiroaki Ikeda, Kenji Chamoto, Takemasa Tsuji, Yoshinori Suzuki, Daiko Wakita, Tsuguhide Takeshima, Takashi Nishimura	122
20	Th1 Cytokine-Conditioned Bone Marrow-Derived Dendritic Cells Can Bypass the Requirement for Th Functions During the Generation of CD8+ CTL 2001 ·The Journal of Immunology ·Marimo Sato, Kenji Chamoto, Takemasa Tsuji, Yoichiro Iwakura, Yuji Togashi, Toshiaki Koda, Takashi Nishimura	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact